AEterna Zentaris to Present at Three Upcoming Conferences in Europe
April 05 2005 - 8:31AM
PR Newswire (US)
AEterna Zentaris to Present at Three Upcoming Conferences in Europe
QUEBEC CITY, April 5 /PRNewswire-FirstCall/ -- AEterna Zentaris
Inc. (TSX: AEZ; Nasdaq: AEZS) today announced that it will present
at three important conferences in France and Italy next week. At
BioSquare, Gilles Gagnon, President and Chief Executive Officer of
the Company, will present a corporate update on Thursday, April 14,
2005, at 9:00 a.m. (local time) in Room Rhone 1, Level 1 of the
Convention Centre of Lyon, in France. At Bio Vision, Mr. Gagnon
will give a presentation entitled "Endocrine Therapy", Thursday,
April 14, 2005, between 3:30 p.m. and 4:00 p.m. (local time) at the
Hilton Hotel in Lyon, France. Also on Thursday, April 14 2005,
AEterna Zentaris will host a Satellite Symposium entitled
"Impavido(R) - The Breakthrough - Oral Leishmaniasis Therapy", at
the 3rd World Conference on Leishmaniasis, at 6:00 p.m. (local
time), at the Citta del Mare Hotel & Resort, in
Palermo-Terrasini, Sicily, Italy. About AEterna Zentaris Inc.
AEterna Zentaris Inc. is an oncology and endocrine therapy focused
biopharmaceutical company with proven expertise in drug discovery,
development and commercialization. The Company's broad 20 product
pipeline leverages five different therapeutic approaches, including
LHRH antagonists and signal transduction inhibitors. The lead LHRH
antagonist compound, cetrorelix, is currently marketed for in vitro
fertilization under the brand name Cetrotide(R). Cetrorelix is also
in late-stage clinical development for endometriosis and benign
prostatic hyperplasia (BPH). The lead signal transduction inhibitor
compound, perifosine, is an orally-active AKT inhibitor that is in
several Phase II trials for multiple cancers. AEterna Zentaris also
owns 61.1% of Atrium Biotechnologies Inc. (TSX: ATB.sv), a leading
developer, manufacturer and marketer of value-added products for
the cosmetics, pharmaceutical, chemical and nutritional industries.
News releases and additional information about AEterna Zentaris are
available on its Web site http://www.aeternazentaris.com/ .
Forward-Looking Statements This press release contains
forward-looking statements made pursuant to the safe harbor
provisions of the U.S. Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks and
uncertainties, which could cause the Company's actual results to
differ materially from those in the forward-looking statements.
Such risks and uncertainties include, among others, the
availability of funds and resources to pursue R&D projects, the
successful and timely completion of clinical studies, the ability
of the Company to take advantage of business opportunities in the
pharmaceutical industry, uncertainties related to the regulatory
process and general changes in economic conditions. Investors
should consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned not to rely on these
forward-looking statements. The Company does not undertake to
update these forward- looking statements. DATASOURCE: AETERNA
ZENTARIS INC. (FORMERLY/ANCIENNEMENT - LES LABORATOIRES AETERNA
CONTACT: Media Relations: Paul Burroughs, (418) 652-8525, ext. 406,
; Investor Relations: Ginette Vallieres, (418) 652-8525, ext. 265,
; Europe: Matthias Seeber, +49-6942602-3425, To request a free copy
of this organization's annual report, please go to
http://www.newswire.ca/ and click on reports@cnw.
Copyright